Gland Pharma LimitedJuly 25, 2024

FDA 483 - Gland Pharma Limited - July 25, 2024

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gland Pharma Limited

Record Details

An FDA inspection of Gland Pharma Limited in Hyderabad, India, identified two significant observations. The firm's quality control unit failed to adequately follow written procedures for monitoring and responding to non-viable particle count excursions. Additionally, the company did not maintain production and control records, specifically CCTV footage of aseptic processing, for the required duration after the drug product's expiration date.

Company: Gland Pharma Limited
Inspection Date: July 25, 2024
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
People: Jeffrey P. Raimondi (Consumer Safety Officer)
Roger F. Zabinski (Investigator)

Open in Dashboard

ID · 56cd5b1f-5d10-4fea-b13f-c9d3d980f6d4